Please ensure Javascript is enabled for purposes of website accessibility

Annapolis-based PharmAthene gets $5.7M DoD contract

ANNAPOLIS — PharmAthene Inc. of Annapolis, a company developing medical defenses against biological and chemical threats, said it has been awarded a $5.7 million, 18-month contract by the U.S. Department of Defense to continue development of a counter-measure to ward off the physical effects of chemical nerve agents.

According to the company, preclinical studies in animals suggest that the treatment, dubbed rBChE, has the potential to provide significant protection against chemical nerve agent poisoning when administered prophylactically (prior to exposure to nerve agent), and also may increase survival when administered therapeutically (following nerve agent exposure).